Efficacy and Safety of PD-1 Inhibitor Plus Rituximab in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

被引：0
|
作者：
Qin, Yan [1 ]
He, Xiaohui [1 ]
Yang, Sheng [1 ]
Liu, Peng [1 ]
Zhou, Shengyu [1 ]
Yang, Jianliang [1 ]
Gui, Lin [1 ]
Zhong, Qiaofeng [1 ]
Zhao, Fengyi [1 ]
Shi, Yuankai [1 ]
Jing, Hongmei [2 ]
Zhang, Shiyue [3 ]
Guo, Ruihan [3 ]
Shi, Yuankai [1 ]
机构：
[1] Chinese Acad Med Sci & Peking Union Med Coll, Beijing Key Lab Clin Study Anticanc Mol Targete, Dept Med Oncol, Natl Canc Ctr,Natl Clin Res Ctr Canc,Canc Hosp, Beijing, Peoples R China
[2] Peking Univ Third Hosp, Dept Hematol, Beijing, Peoples R China
[3] Shanghai Junshi Biosci, Shanghai, Peoples R China
来源：
BLOOD | 2021年 / 138卷
关键词：
D O I：
10.1182/blood-2021-152094
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
2485
引用
收藏
页数：3
相关论文
共 50 条
  • [1] Efficacy and safety of PD-1 monoclonal antibody plus rituximab in relapsed/refractory diffuse large B cell lymphoma patients
    Qin, Yan
    He, Xiaohui
    Chen, Xinrui
    Xie, Zucheng
    Yang, Jianliang
    Yang, Sheng
    Liu, Peng
    Zhou, Shengyu
    Zhang, Changgong
    Gui, Lin
    Shi, Yuankai
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2023, 111 (03) : 356 - 364
  • [2] Safety and Efficacy of Rituximab Plus Bendamustine in Relapsed or Refractory Diffuse Large B-Cell Lymphoma Patients
    Arcari, Annalisa
    Chiappella, Annalisa
    Valenti, Vanessa
    Zanlari, Luca
    Tani, Monica
    Marasca, Roberto
    Cabras, Maria Giuseppina
    Spina, Michele
    Santagostino, Alberto
    Ilariucci, Fiorella
    Carli, Giuseppe
    Musto, Pellegrino
    Savini, Paolo
    Marino, Dario
    Ghio, Francesco
    Gentile, Massimo
    Cox, Maria Christina
    Della Seta, Roberta
    Vallisa, Daniele
    BLOOD, 2014, 124 (21)
  • [3] Efficacy and Safety of PD-1 Inhibitor Plus GVD Chemotherapy in Patients with Relapsed/Refractory Primary Mediastinal Large B-Cell Lymphoma (rrPMLBCL)
    Mei, Qian
    Zhang, Wenying
    Liu, Yang
    Yang, Qingming
    Rasko, John E. J.
    Han, Weidong
    BLOOD, 2019, 134
  • [4] Efficacy and safety of lenalinomide combined with rituximab in patients with relapsed/refractory diffuse large B-cell lymphoma
    Ivanov, Vadim
    Coso, Diane
    Chetaille, Bruno
    Esterni, Benjamin
    Olive, Daniel
    Aurran-Schleinitz, Therese
    Schiano, Jean Marc
    Stoppa, Anne-Marie
    Broussais-Guillaumot, Florence
    Blaise, Didier
    Bouabdallah, Reda
    LEUKEMIA & LYMPHOMA, 2014, 55 (11) : 2508 - 2513
  • [5] Bendamustine plus rituximab in Japanese patients with relapsed or refractory diffuse large B-cell lymphoma
    Kayoko Murayama
    Toru Kiguchi
    Koji Izutsu
    Yoshihiro Kameoka
    Michihiro Hidaka
    Harumi Kato
    Shinya Rai
    Junya Kuroda
    Kenichi Ishizawa
    Satoshi Ichikawa
    Kiyoshi Ando
    Michinori Ogura
    Koji Fukushima
    Yasuhito Terui
    Annals of Hematology, 2022, 101 : 979 - 989
  • [6] Bendamustine plus rituximab in Japanese patients with relapsed or refractory diffuse large B-cell lymphoma
    Murayama, Kayoko
    Kiguchi, Toru
    Izutsu, Koji
    Kameoka, Yoshihiro
    Hidaka, Michihiro
    Kato, Harumi
    Rai, Shinya
    Kuroda, Junya
    Ishizawa, Kenichi
    Ichikawa, Satoshi
    Ando, Kiyoshi
    Ogura, Michinori
    Fukushima, Koji
    Terui, Yasuhito
    ANNALS OF HEMATOLOGY, 2022, 101 (05) : 979 - 989
  • [7] Safety and efficacy of rituximab plus bendamustine in relapsed or refractory diffuse large B-cell lymphoma patients: an Italian retrospective multicenter study
    Arcari, Annalisa
    Chiappella, Annalisa
    Spina, Michele
    Zanlari, Luca
    Bernuzzi, Patrizia
    Valenti, Vanessa
    Tani, Monica
    Marasca, Roberto
    Cabras, Maria Giuseppina
    Zambello, Renato
    Santagostino, Alberto
    Ilariucci, Fiorella
    Carli, Giuseppe
    Musto, Pellegrino
    Savini, Paolo
    Marino, Dario
    Ghio, Francesco
    Gentile, Massimo
    Cox, Maria Christina
    Vallisa, Daniele
    LEUKEMIA & LYMPHOMA, 2016, 57 (08) : 1823 - 1830
  • [8] Bendamustine plus Rituximab as Treatment for Elderly Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma
    Vacirca, Jeffrey
    Tabbara, Imad
    Acs, Peter
    Shumaker, Grace
    BLOOD, 2010, 116 (21) : 1157 - 1157
  • [9] Efficacy and safety of lenalidomide in relapsed/refractory diffuse large B-cell lymphoma
    Habermann, T.
    Lossos, I.
    Justice, G.
    Tuscano, J.
    Cole, C.
    Vose, J.
    Pietronigro, D.
    Takeshita, K.
    Ervin-Haynes, A.
    Zeldis, J.
    Wiernik, P.
    ANNALS OF ONCOLOGY, 2008, 19 : 150 - 150
  • [10] Efficacy and Safety of Lenalidomide, Anti-PD-1 Antibody Combined with Orelabrutinib or Rituximab in the Treatment of Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma
    Qing, Miao
    Huang, Yongfen
    Chen, Can
    Wang, Lingling
    Feng, Jun
    Xu, Chuanhai
    Cheng, Yuexin
    Dong, Jianming
    Zhang, Linlin
    Xu, Hao
    BLOOD, 2022, 140 : 3769 - 3770
12345